JP5335241B2 - 抗微生物ヘキサペプチド - Google Patents

抗微生物ヘキサペプチド Download PDF

Info

Publication number
JP5335241B2
JP5335241B2 JP2007555158A JP2007555158A JP5335241B2 JP 5335241 B2 JP5335241 B2 JP 5335241B2 JP 2007555158 A JP2007555158 A JP 2007555158A JP 2007555158 A JP2007555158 A JP 2007555158A JP 5335241 B2 JP5335241 B2 JP 5335241B2
Authority
JP
Japan
Prior art keywords
seq
hexapeptide
kfkwpw
peptide
activity
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2007555158A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008537537A (ja
JP2008537537A5 (enExample
Inventor
ジェイ． ファラ，ティモシー
チャン，リージュワン
エム． ハリス，スコット
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Helix Biomedix Inc
Original Assignee
Helix Biomedix Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Helix Biomedix Inc filed Critical Helix Biomedix Inc
Publication of JP2008537537A publication Critical patent/JP2008537537A/ja
Publication of JP2008537537A5 publication Critical patent/JP2008537537A5/ja
Application granted granted Critical
Publication of JP5335241B2 publication Critical patent/JP5335241B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Birds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Medicinal Preparation (AREA)
JP2007555158A 2005-02-09 2006-02-07 抗微生物ヘキサペプチド Active JP5335241B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US65127005P 2005-02-09 2005-02-09
US60/651,270 2005-02-09
PCT/US2006/004147 WO2006086321A2 (en) 2005-02-09 2006-02-07 Antimicrobial hexapeptides

Publications (3)

Publication Number Publication Date
JP2008537537A JP2008537537A (ja) 2008-09-18
JP2008537537A5 JP2008537537A5 (enExample) 2009-04-02
JP5335241B2 true JP5335241B2 (ja) 2013-11-06

Family

ID=36793611

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2007555158A Active JP5335241B2 (ja) 2005-02-09 2006-02-07 抗微生物ヘキサペプチド

Country Status (13)

Country Link
US (1) US7407940B2 (enExample)
EP (1) EP1853620B1 (enExample)
JP (1) JP5335241B2 (enExample)
KR (1) KR101306643B1 (enExample)
CN (1) CN101155825B (enExample)
AT (1) ATE540969T1 (enExample)
AU (1) AU2006212922B2 (enExample)
CA (1) CA2597191C (enExample)
DK (1) DK1853620T3 (enExample)
ES (1) ES2378242T3 (enExample)
PL (1) PL1853620T3 (enExample)
SI (1) SI1853620T1 (enExample)
WO (1) WO2006086321A2 (enExample)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070207112A1 (en) * 2005-12-07 2007-09-06 Grant Industries, Inc. Anti-acne composition
IL172896A0 (en) * 2005-12-29 2006-06-11 Yeda Res & Dev Cxcr4 inhibition
US8168181B2 (en) 2006-02-13 2012-05-01 Alethia Biotherapeutics, Inc. Methods of impairing osteoclast differentiation using antibodies that bind siglec-15
EP2438962A3 (en) 2006-02-13 2012-07-18 Alethia Biotherapeutics Inc. Polynucleotides and polypeptide sequences involved in the process of bone remodeling
US8906859B2 (en) * 2006-11-10 2014-12-09 Cera Therapeutics, Inc. Uses of kappa opioid synthetic peptide amides
US7842662B2 (en) 2006-11-10 2010-11-30 Cara Therapeutics, Inc. Synthetic peptide amide dimers
US8236766B2 (en) * 2006-11-10 2012-08-07 Cara Therapeutics, Inc. Uses of synthetic peptide amides
RU2500685C2 (ru) * 2006-11-10 2013-12-10 Кара Терапеутикс, Инк Синтетические пептидные амиды
US7713937B2 (en) * 2006-11-10 2010-05-11 Cara Therapeutics, Inc. Synthetic peptide amides and dimeric forms thereof
CN101622271B (zh) * 2007-01-16 2014-08-27 加利福尼亚大学董事会 抗微生物肽
KR100879220B1 (ko) 2007-11-12 2009-01-19 아주대학교산학협력단 식물병원성 세균에 대한 항미생물 펩티드 ｋｃｍ２１
KR100879221B1 (ko) 2007-11-12 2009-01-19 아주대학교산학협력단 식물병원성 세균에 대한 항미생물 펩티드 ｋｒｓ２２
GB0724951D0 (en) 2007-12-20 2008-01-30 Lytix Biopharma As Compounds
WO2009146885A2 (en) * 2008-06-02 2009-12-10 Spiderbiotech S.R.L. Lipidated antibacterial peptides
GB0818074D0 (en) * 2008-10-02 2008-11-05 Lytix Biopharma As Treatment of biofilms
GB0818072D0 (en) 2008-10-02 2008-11-05 Lytix Biopharma As Compounds
GB0918579D0 (en) 2009-10-22 2009-12-09 Imp Innovations Ltd Gadd45beta targeting agents
JP2013511554A (ja) * 2009-11-23 2013-04-04 パラティン テクノロジーズ，インコーポレイテッド メラノコルチン−１受容体特異的線状ペプチド
US9017692B2 (en) * 2011-12-05 2015-04-28 Ohio State Innovation Foundation Antimicrobial agent, bacterial strain, biosynthesis, and methods of use
JP6382111B2 (ja) * 2012-03-01 2018-08-29 ノヴォ ノルディスク アー／エス Ｎ末端改変オリゴペプチド及びその使用
IN2014KN02933A (enExample) 2012-07-19 2015-05-08 Alethia Biotherapeutics Inc
FR3002452B1 (fr) * 2013-02-28 2016-02-12 Dermaconcept Jmc Composition dermatologique antimicrobienne topique
TWI577697B (zh) * 2013-11-28 2017-04-11 國立清華大學 耐高鹽及抗蛋白之抗菌胜肽及其製造方法
KR102092831B1 (ko) 2015-01-16 2020-03-24 가부시키가이샤 만다무 클렌징 로션, 시트 화장료 및 미용 방법
US9738684B2 (en) 2015-06-29 2017-08-22 Council Of Scientific & Industrial Research N-terminally modified linear and branched polyamine conjugated peptidomimetics as antimicrobials agents
KR101855170B1 (ko) * 2015-11-18 2018-05-08 (주)노바셀테크놀로지 신규 항균 펩타이드 및 그의 용도
CN109942713A (zh) * 2018-12-28 2019-06-28 广州医科大学 新型抗菌肽及其应用
KR102170236B1 (ko) * 2019-03-19 2020-10-29 (주)노바셀테크놀로지 신규 다중 기능성 펩타이드 및 그의 용도
EP3965887B1 (en) 2019-05-06 2024-02-28 Université de Genève Antimicrobial chitosan
CN110950932B (zh) * 2020-01-09 2023-04-18 福州大学 一种修饰肽的制备及其应用
KR102220323B1 (ko) * 2020-05-15 2021-02-26 (주)노바셀테크놀로지 신규 다중 기능성 펩타이드 및 그의 용도
KR102429281B1 (ko) * 2020-05-25 2022-08-05 (주)노바셀테크놀로지 신규 안구건조증 치료용 약학적 조성물
KR102486996B1 (ko) * 2020-09-04 2023-01-10 서울대학교병원 펩타이드 및 이를 포함하는 피부 주름 개선용 조성물 및 대사성 질환 치료용 조성물
CN111925422B (zh) * 2020-09-17 2021-05-18 张雪山 抗菌肽及其在制备药物或化妆品中的应用
CN113248572B (zh) * 2021-04-30 2023-04-11 重庆理工大学 一种抗多重耐药菌环肽及其应用
CZ309857B6 (cs) 2022-03-31 2023-12-20 Contipro A.S. Hexapeptid, kompozice zahrnující tento hexapeptid a jejich topické použití
CN116332777A (zh) * 2023-02-20 2023-06-27 华中科技大学 二芳基苯甲胺类化合物、制备及作为载体合成多肽的应用
CN116041422B (zh) * 2023-03-31 2023-06-16 四川大学 自组装抗菌肽及其组合物、药物载体、载药体系和用途

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4355104A (en) 1980-06-17 1982-10-19 Kabigen Ab Bacteriolytic proteins
US4520016A (en) 1980-06-17 1985-05-28 Kabigen Ab Bacteriolytic proteins
US5861478A (en) 1987-07-06 1999-01-19 Helix Biomedix, Inc. Lytic peptides
CA1327311C (en) 1987-07-06 1994-03-01 Jesse M. Jaynes Therapeutic antimicrobial polypeptides, their use and methods for preparation
DE3854476T2 (de) 1987-07-06 1996-04-04 Univ Louisiana State Inhibierung von eukaryotischen pathogenen und neoplasmen mit lytischen peptiden.
EP0470974B1 (en) 1989-04-10 2000-01-26 Helix BioMedix, Inc. Lytic peptides, use for growth, infection and cancer
EP0579763A4 (en) 1991-04-08 1994-12-21 Magainin Pharma NOVEL PEPTIDE COMPOSITIONS AND USES.
US5858974A (en) * 1995-07-20 1999-01-12 Xoma Corporation Anti-fungal peptides
US5561107A (en) 1993-06-04 1996-10-01 Demeter Biotechnologies, Ltd. Method of enhancing wound healing by stimulating fibroblast and keratinocyte growth in vivo, utilizing amphipathic peptides
US5955573A (en) 1993-06-04 1999-09-21 Demegen, Inc. Ubiquitin-lytic peptide fusion gene constructs, protein products deriving therefrom, and methods of making and using same
WO1994028921A1 (en) 1993-06-04 1994-12-22 Demeter Biotechnologies, Ltd. Method of treating pulmonary disease states with non-naturally occurring amphipathic peptides
WO1995013085A1 (en) 1993-11-08 1995-05-18 Demeter Biotechnologies Ltd. Methylated lysine-rich lytic peptides and method of making same by reductive alkylation
AU693518B2 (en) * 1994-01-18 1998-07-02 Magainin Pharmaceuticals, Inc. Ion-channel forming amphiphilic peptides having n-terminal modifications
US5789542A (en) 1994-04-22 1998-08-04 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Amphipathic peptides
IL114697A0 (en) 1994-07-22 1995-11-27 Demeter Biotech Ltd Polypeptides comprising ubiquitin-lytic peptide fusion protein products deriving therefrom their preparation and use
WO1997021728A1 (en) 1995-12-12 1997-06-19 Karolinska Innovations Ab PEPTIDE BINDING THE KLVFF-SEQUENCE OF AMYLOID $g(b)
US6566334B1 (en) 1997-02-06 2003-05-20 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Short amphipathic peptides with activity against bacteria and intracellular pathogens
US6635740B1 (en) 1997-03-27 2003-10-21 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Ligand/lytic peptide compositions and methods of use
WO2001049834A2 (en) 2000-01-06 2001-07-12 Monsanto Technology Llc Preparation of deallergenized patatin proteins and patatin permutein proteins
EP1292609A2 (en) * 2000-06-16 2003-03-19 Hercules Incorporated Peptides, compositions and methods for the treatment of burkholderia cepacia
EP1402001A4 (en) * 2001-05-04 2006-05-24 Scripps Research Inst ANTIMICROBIAL PEPTIDES AND COMPOSITIONS

Also Published As

Publication number Publication date
JP2008537537A (ja) 2008-09-18
WO2006086321A2 (en) 2006-08-17
AU2006212922A1 (en) 2006-08-17
EP1853620A2 (en) 2007-11-14
CA2597191A1 (en) 2006-08-17
CN101155825B (zh) 2014-11-26
KR101306643B1 (ko) 2013-09-12
KR20070107748A (ko) 2007-11-07
DK1853620T3 (da) 2012-03-26
US7407940B2 (en) 2008-08-05
CA2597191C (en) 2014-04-01
AU2006212922B2 (en) 2011-04-21
SI1853620T1 (sl) 2012-03-30
EP1853620B1 (en) 2012-01-11
WO2006086321A3 (en) 2007-02-22
ES2378242T3 (es) 2012-04-10
PL1853620T3 (pl) 2012-07-31
ATE540969T1 (de) 2012-01-15
CN101155825A (zh) 2008-04-02
US20060229252A1 (en) 2006-10-12

Similar Documents

Publication Publication Date Title
JP5335241B2 (ja) 抗微生物ヘキサペプチド
KR102137941B1 (ko) 항균 펩티드
JP5688290B2 (ja) 抗菌性ペプチド
CN101528248B (zh) 抗微生物肽
JP6964577B2 (ja) 抗菌性ペプチド及びその使用方法
CA2441562C (en) Short bioactive peptides and methods for their use
André et al. Structure–activity relationship-based optimization of small temporin-SHf analogs with potent antibacterial activity
US10435437B2 (en) Modified apidaecin derivatives as antibiotic peptides
WO2012145680A2 (en) Anti-microbial peptides and uses therefore
US20050282755A1 (en) Compositions having antimicrobial activity and uses thereof
CA2312191A1 (en) Threonine-containing protegrins
JPH06511234A (ja) Ｃ末端置換を有する生物活性ペプチド組成物および治療法
WO2006127715A1 (en) Antimicrobial peptides
Kuhn-Nentwig et al. Cupiennin 1d*: the cytolytic activity depends on the hydrophobic N-terminus and is modulated by the polar C-terminus
US20240254175A1 (en) Novel selective antimicrobial fusion peptides

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20090204

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20090204

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20110906

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20111201

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20120904

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20121129

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20130219

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130408

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20130723

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20130731

R150 Certificate of patent or registration of utility model

Ref document number: 5335241

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250